Our progress towards environmental sustainability | Takeda Pharmaceuticals

• In 2020, the Science-Based Targets initiative (SBTi) recognized Takeda’s goals as being consistent with reductions required to limit the rise in global temperature to 1.5°C above pre-industrial levels.

• We were recognized in the 2022 Dow Jones Sustainability Asia Pacific Index for the 13^th consecutive year.

• We were included on CDP’s 2022 A list for climate change leadership and transparency.

• We received two WorldStar Global Packaging Awards from the World Packaging Organization for our pioneering use of bio-polyethylene (bio-PE) in pharmaceutical primary packaging and secondary packaging for pre-filled syringes.

• We were recognized as Green Lease Leader for incorporating sustainability into our global leasing practices.

• Our quality lab in Singapore has been certified green lab with the highest possible level of certification from My Green Lab, a non-profit organization.

• We achieved carbon neutrality in our value chain from fiscal year 2020 (for fiscal year 2019 GHG emissions) and have maintained the status since.

• We are on track to eliminate 40% of our Scope 1 and 2 GHG emissions by FY2025. We’re aiming to eliminate them altogether before 2035.

• We initiated a global Climate Action Program at Sites (CAPS) that drives initiatives locally to reduce our GHG emissions, energy use and freshwater withdrawals.

• We diverted 80% of waste from landfill and are on track to achieve 90% or greater total waste-to-landfill diversion by FY2025.

• We partnered with key suppliers to help them establish science-based carbon emissions reduction goals and take additional actions to reduce their emissions in line with the targets they set.

• We joined the Race to Zero campaign – the largest ever alliance committed to eliminating carbon emissions by 2050 at the latest.

• We support the Energize program, a collaboration between 19 global pharmaceutical companies to engage their suppliers in bold climate action and decarbonization of the pharmaceutical value chain through renewable energy procurement.

• In 2022, we signed a virtual power purchase agreement advancing renewable energy production in the U.S. accounting for approximately 20% of Takeda’s operational GHG emissions.

We’re proud of our progress, and we know there is more we need to do to contribute to environmental sustainability.

As we look to the future, we aspire to build a sustainable future for patients, people and the planet. We’re taking action to reduce our environmental impacts throughout the lifecycles of our products and through the way we work. We’re improving our own ways of working, assisting our suppliers and partners in their commitments and efforts, partner with technology and environmental experts as well as rallying people worldwide.